Co‐administration of the prostaglandin F2α receptor antagonist pre‐term labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone

Oliver Pohl, Line Marchand, Jean‐Pierre Gotteland, Simon Coates, Jörg Täubel, Ulrike Lorch

Pohl, O, Marchand, L, Gotteland, J‐P, Coates, S, Täubel, J, Lorch, U. Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone. Br J Clin Pharmacol. 2019; 85: 1516– 1527.https://doi.org/10.1111/bcp.13925

Safety and Pharmacokinetics of the Oral Prostaglandin F2alpha Receptor Antagonist, OBE022, in Patients With Threatened Spontaneous Preterm Labor

Andrew Humberstone, Jose Luis Bartha, Seppo Heinonen, Juha Räsänen, Aydin Tekay, Michel Brethous, Jean-Pierre Gotteland, Oliver Pohl, Ernest Loumaye

SRI Conference, 12-16 March 2019, Paris, France
Abstract S-001: page 299A

Abstracts. Reprod. Sci. 26, A62–A390 (2019). https://doi.org/10.1177/1933719119834079

Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs

Simon Coates, Oliver Pohl, Jean-Pierre Gotteland, Jörg Täubel, Ulrike Lorch

Article first published online: January 27, 2019

Coates S, Pohl O, Gotteland JP, Täubel J, Lorch U. Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs. Ther Innov Regul Sci. 2020;54(1):184‐194. doi:10.1007/s43441-019-00044-y

OBE022, an oral and selective prostaglandin F2α receptor antagonist as an effective and safe modality for the treatment of preterm labor

Pohl O, Chollet A, Kim SH, Riaposova L, Spezia F, Gervais F, Guillaume P, Lluel P, Meen M, Lemaux F, Terzidou V, Bennett PR, Gotteland JP.

Journal of Pharmacology and Experimental Therapeutics August 2018, 366 (2) 349-364; doi:10.1124/jpet.118.247668

Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women

Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U

Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U. Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women. Br J Clin Pharmacol. 2018;84(8):1839‐1855. doi:10.1111/bcp.13622

Effects of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022 on Reproduction in Rats and Rabbits

Oliver Pohl, Roberta Sisti, Jean-Pierre Gotteland

SRI Conference, 06-10 March 2018, San Diego, CA
Abstract S-037: page 265A

Reproductive Sciences Vol. 25, Supplement 1, March 2018 265A Abstract S-037

Safety and Pharmacokinetics of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022: A First-in-Human Study in Healthy Women

Oliver Pohl, Ulrike Lorch, Line Marchand, Jean-Pierre Gotteland

SRI Conference, 06-10 March 2018, San Diego, CA
Abstract S-038: Pages 265A-266A

Reproductive Sciences Vol. 25, Supplement 1, March 2018 265A-266A Abstract S-038

Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG Assessments

Jörg Täubel, Ulrike Lorch, Simon Coates, Sara Fernandes, Paul Foley, Georg Ferber, Jean-Pierre Gotteland, Oliver Pohl

Täubel, J., Lorch, U., Coates, S., Fernandes, S., Foley, P., Ferber, G., Gotteland, J.‐P. and Pohl, O. (2018), Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First‐in‐Human Study in Healthy Subjects, Using Intensive ECG Assessments. Clinical Pharmacology in Drug Development, 7: 889-900. doi:10.1002/cpdd.447

Confirmation of the Cardiac Safety of OBE022 in a First in Human Study in Healthy Subjects using Intensive ECG Assessments and the Effect of a Meal on QTc to Show Assay Sensitivity

J. Täubel, U. Lorch , G. Ferber , O Pohl

ACCP Conference, 17-19 September 2017, San Diego, CA
Poster 019: Page 16

Volume6, IssueS1, Special Issue: 2017 Annual Meeting American College of Clinical Pharmacology, September 2017, doi:full/10.1002/cpdd.385

FP receptor antagonist, OBE002, inhibits both PGF2α- and OT-induced contractions of human pregnant myometrium in vitro

L. Riaposova, S.H. Kim, O. Pohl, A. Chollet, J.P. Gotteland, A. Hanyaloglu, P. Bennett, V. Terzidou

ESHRE 33rd Annual Meeting, 2-5 July 2017, Geneva, Switzerland
Abstract P-692: Page i452

Abstracts of the 33rd Annual Meeting of the European Society of Human Reproduction and Embryology, Human Reproduction, Volume 32, Issue suppl_1, July 2017, Pages i1–i539